Up to $40m will be invested and 75 jobs will be created as Pfizer’s Grange Castle site joins global supply chain.
Pfizer’s Grange Castle facility is to form part of the global supply chain network for Pfizer and BioNTech’s Covid-19 vaccine, the company confirmed today (19 May).
Since Pfizer and BioNTech started distributing their COVID-19 vaccine in December 2020, the companies have made several enhancements to the vaccine’s supply chain.
“This is a very significant moment for Ireland and for our Grange Castle site”
These enhancements include expanding their existing facilities, adding more suppliers, and bringing on additional Pfizer/BioNTech sites and contract manufacturers around the world to produce the vaccine.
As such, Pfizer is now bringing on additional European-based facility to be a part of the global Pfizer-BioNTech COVID-19 Vaccine supply chain network and Grange Castle (Ireland) will contribute to the worldwide supply of the vaccine.
Up to approximately $40m will be invested in Grange Castle and an additional 75 roles will be recruited.
Pfizer’s Grange Castle facility will produce the mRNA drug substance. Given the extensive technical transfer process, on-site development, equipment installation and regulatory approvals needed for the site, the company expects it will be brought onto the network by the end of 2021.
“This is a very significant moment for Ireland and for our Grange Castle site,” said Dr Paul Duffy, vice-president of Pfizer Global Supply.
“We are immensely proud to be able to play a part in manufacturing Pfizer’s Covid-19 vaccine.
“Since last year, Pfizer in partnership with BioNTech has worked tirelessly to expedite the development, approval and scale-up of our Covid-19 vaccine.
“The company has continually expanded manufacturing capability and external partnerships to deliver increased doses to the world to help defeat this devastating pandemic,” Dr Duffy said.
By John Kennedy (email@example.com)
Published: 19 May 2021